Operational Research for Cryptococcal Antigen Screening
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This will be a stepped wedge randomized trial design to evaluate the implementation of
cryptococcal antigen (CRAG) screening and preemptive anti-fungal therapy of HIV-infected
persons entering antiretroviral therapy (ART) outpatient treatment in Uganda. Those who are
ART eligible with a CD4≤100 cells/mcL will have a serum/plasma CRAG performed by lateral flow
assay. Those who are CRAG-positive and asymptomatic will be treated with high dose
fluconazole. After 6 months survival with retention-in-care will be compared between those
who are CRAG+ and CRAG negative
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
Centers for Disease Control and Prevention Infectious Diseases Institute, Uganda Makerere University